Literature DB >> 12165499

Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain.

Govindarajan Rajagopalan1, Michele K Smart, Christopher J Krco, Chella S David.   

Abstract

Invariant chain (Ii) is a non-MHC-encoded molecule, which plays an accessory role in the proper assembly/expression of functional MHC class II molecules and there by plays an important role in Ag processing/presentation. The phenotype of mice lacking Ii depends on the allotype of the MHC class II molecule. In some mice strains, Ii deficiency results in reduction in expression of class II molecules accompanied by defective CD4(+) T cell development. Responses to conventional Ags/superantigens are also compromised. In this study, we describe for the first time the functionality of human class II molecules, HLA-DQ6 and HLA-DQ8, in transgenic mice lacking Ii. HLA transgenic Ii(-/-) mice expressed very low levels of surface DQ6 and DQ8 accompanied by severe reduction in CD4(+) T cells both in the thymus and periphery. In vitro proliferation and cytokine production to an exogenous superantigen, staphylococcal enterotoxin B (SEB) was diminished in HLA-transgenic Ii(-/-) mice. However, SEB-induced in vivo expansion of CD8(+) T cells expressing TCR Vbeta8 family in DQ8.Ii(-/-) mice was comparable with that of DQ8.Ii(+/+) mice. Systemic IFN-gamma production following in vivo challenge with SEB was reduced in DQ8.Ii(-/-) mice and were also protected from SEB-induced toxic shock. Although the T cell response to a known peptide Ag was diminished in DQ8.Ii(-/-) mice, DQ8.Ii(-/-) APCs were capable of presenting that peptide to primed T cells from wild-type DQ8 mice as well as to a specific T cell hybridoma. Differentiation of mature B cells was also affected to a certain extent in DQ8.Ii(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165499     DOI: 10.4049/jimmunol.169.4.1774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists.

Authors:  Govindarajan Rajagopalan; Moon M Sen; Chella S David
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

2.  Human leukocyte antigen class II transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome.

Authors:  Ashenafi Y Tilahun; Eric V Marietta; Tsung-Teh Wu; Robin Patel; Chella S David; Govindarajan Rajagopalan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  Concomitant Disruption of CD4 and CD8 Genes Facilitates the Development of Double Negative αβ TCR+ Peripheral T Cells That Respond Robustly to Staphylococcal Superantigen.

Authors:  Vaidehi R Chowdhary; Ashton Krogman; Ashenafi Y Tilahun; Mariam P Alexander; Chella S David; Govindarajan Rajagopalan
Journal:  J Immunol       Date:  2017-05-03       Impact factor: 5.422

4.  Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice.

Authors:  Govindarajan Rajagopalan; Koji Iijima; Manisha Singh; Hirohito Kita; Robin Patel; Chella S David
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay.

Authors:  E Cook; X Wang; N Robiou; B C Fries
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

6.  Chronic exposure to staphylococcal superantigen elicits a systemic inflammatory disease mimicking lupus.

Authors:  Vaidehi R Chowdhary; Ashenafi Y Tilahun; Chad R Clark; Joseph P Grande; Govindarajan Rajagopalan
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

7.  The impact of Staphylococcus aureus-associated molecular patterns on staphylococcal superantigen-induced toxic shock syndrome and pneumonia.

Authors:  Ashenafi Y Tilahun; Melissa Karau; Alessandro Ballard; Miluka P Gunaratna; Anusa Thapa; Chella S David; Robin Patel; Govindarajan Rajagopalan
Journal:  Mediators Inflamm       Date:  2014-06-12       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.